Texas Permanent School Fund cut its position in Anika Therapeutics, Inc. (NASDAQ:ANIK – Get Rating) by 6.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,733 shares of the biotechnology company’s stock after selling 665 shares during the period. Texas Permanent School Fund owned 0.07% of Anika Therapeutics worth $288,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently made changes to their positions in the company. Fisher Asset Management LLC boosted its stake in shares of Anika Therapeutics by 11.4% in the fourth quarter. Fisher Asset Management LLC now owns 133,013 shares of the biotechnology company’s stock worth $3,937,000 after acquiring an additional 13,622 shares during the last quarter. Legato Capital Management LLC purchased a new position in Anika Therapeutics during the fourth quarter worth approximately $224,000. Louisiana State Employees Retirement System purchased a new position in Anika Therapeutics during the fourth quarter worth approximately $204,000. Riverwater Partners LLC purchased a new position in Anika Therapeutics during the fourth quarter worth approximately $289,000. Finally, Bank of New York Mellon Corp lifted its position in Anika Therapeutics by 9.1% during the third quarter. Bank of New York Mellon Corp now owns 150,481 shares of the biotechnology company’s stock worth $3,582,000 after buying an additional 12,531 shares in the last quarter. 91.57% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
ANIK has been the topic of a number of analyst reports. StockNews.com initiated coverage on Anika Therapeutics in a research report on Thursday. They set a “hold” rating on the stock. Barrington Research downgraded Anika Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 7th. Finally, Stephens restated an “equal weight” rating and issued a $28.00 target price on shares of Anika Therapeutics in a research report on Friday, April 14th.
Anika Therapeutics Trading Up 2.1 %
Anika Therapeutics (NASDAQ:ANIK – Get Rating) last posted its quarterly earnings data on Monday, March 6th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06). The firm had revenue of $39.62 million during the quarter, compared to analysts’ expectations of $38.32 million. Anika Therapeutics had a negative net margin of 14.15% and a negative return on equity of 3.77%. Research analysts predict that Anika Therapeutics, Inc. will post -1.13 EPS for the current fiscal year.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body.
- Get a free copy of the StockNews.com research report on Anika Therapeutics (ANIK)
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
- Foot Locker And The Ebbing Tide Of Discretionary Spending
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics, Inc. (NASDAQ:ANIK – Get Rating).
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.